Aytu Biopharma, INC 10-K annual reports
Annual reports — audited financials, the full risk-factor list, and management’s account of the year.
NASDAQ
Aytu BioPharma's fiscal year 2026 results show a net revenue decrease of 13.3% to $57.6 million, driven by declines in its ADHD and Pediatric portfolios, while launching its new MDD treatment, EXXUA.
NASDAQ
Aytu BioPharma licenses EXXUA for MDD and raises $16.6M to support commercialization.
NASDAQ
Aytu BioPharma reports a net loss of $15.8 million for fiscal year 2024, while strategically shifting focus to its Rx segment and completing the divestiture of its Consumer Health segment.